comparemela.com

Latest Breaking News On - Covid 19 drug development - Page 7 : comparemela.com

Cipla to market and distribute Roche s antibody cocktail (Casirivimab and Imdevimab) in India

For treatment of mild to moderate Covid-19Roche India today announced that the Central Drugs Standards Control Organisation (CDSCO) has provided an Emergency Use Authorisation (EUA) for Roche s antibody cocktail (Casirivimab and Imdevimab) in India. This approval was based on the data that have been filed for the EUA in the United States, and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union. This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla.

States allocated 34 5 lakh vials of Remdesivir so far: Sadananda Gowda

India approves antibody cocktail to treat COVID-19

© Getty Images India on Wednesday granted emergency use authorization for an antibody cocktail used to treat COVID-19 as the country battles a devastating surge in coronavirus cases. The approval for the drug, developed by Roche and Regeneron, was based on data filed by the U.S. and the “scientific opinion” of the Committee for Medicinal Products for Human Use, a European Union medical agency, according to a press release from Indian pharmaceutical company Cipla. The drug is meant for high-risk patients who fall ill with mild to moderate cases of COVID-19. It has been shown to reduce the risk of hospitalization or death by 70 percent, compared to a placebo, according to Cipla.

Lilly hit by staff accusations, FDA scrutiny at Covid-19 drug factories

Read more about Lilly hit by staff accusations, FDA scrutiny at Covid-19 drug factories on Business Standard. (Reuters) - Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker s COVID-19

Substantial increase in remdesivir production, allotment to states: Gowda

This will make India s fight stronger against COVID-19, the Chemicals & Fertilizers Minister said. In a tweet Gowda said, After detailed review of state wise allotment of #Remdesivir with @Pharmadept substantial increase has been made in overall production & allotment to all states . A total of 16 lakh remdesivir vials are being allocated to the states and union territories from April 21to April 30, 2021, Gowda said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.